跳转至内容
Merck
CN

L1167

拉坦前列素

≥98% (HPLC)

别名:

异丙基 (5Z,9α,11α,15R)-9,11,15-三羟基-17-苯基-18,19,20-三硝基苯-5-烯-1-酸酯, 异丙基 ( Z )-7-[(1 R ,2 R ,3 R ,5 S )-3,5-二羟基-2-[(3 R )-3-羟基-5-苯戊基] 环戊基] 庚烯-5-酸酯, 适利达

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C26H40O5
化学文摘社编号:
130209-82-4
分子量:
432.59
NACRES:
NA.77
PubChem Substance ID:
24724523
UNSPSC Code:
12352200
MDL number:
MFCD00216074

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

拉坦前列素, ≥98% (HPLC)

InChI

1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1

SMILES string

CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc2ccccc2

InChI key

GGXICVAJURFBLW-CEYXHVGTSA-N

assay

≥98% (HPLC)

form

oil

color

colorless to yellow

solubility

DMSO: freely soluble
methanol: soluble

originator

Johnson & Johnson

shipped in

wet ice

storage temp.

−20°C

Quality Level

100

Gene Information

human ... PTGFR(5737)

正在寻找类似产品? 访问 产品对比指南

相关类别

Application

拉坦前列素已被用于：
  • 制备包含姜黄素纳米颗粒（CUR-NP）的热敏水凝胶，以确定其在氧化应激下对人小梁网（TM）细胞的治疗作用。
  • 作为酯类前药用于研究其对小鼠鼠眼表面的作用
  • 制备热敏水凝胶用于研究其对控制高眼压症的作用。

Biochem/physiol Actions

拉坦前列素是一种强效、选择性前列腺素F2 α类似物受体激动剂。它在角膜中被酯酶水解为拉坦前列素酸的生物活性形式。拉坦前列素在降低眼内压（IOP）方面起一定作用，因此它具有治疗青光眼的疗效。

Features and Benefits

《受体分类和信号转导》手册的 前列腺素类受体 页面有该化合物的介绍。想要浏览手册的其他页面， 请单击此处。
该化合物由 Johnson & Johnson 开发。如需浏览其他制药公司开发的化合物和批准的药物/候选药物列表，请点击此处。

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361d

Hazard Classifications

Repr. 2

存储类别

10 - Combustible liquids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000507883
0000507891
0000507891
0000507883
0000504536

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Anastasios G P Konstas et al.
The British journal of ophthalmology, 97(12), 1510-1515 (2013-05-18)
To compare 24 h intraocular pressure (IOP) control obtained with preservative free (PF) tafluprost 0.0015% versus branded preservative containing latanoprost 0.005% administered as first choice monotherapy in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT). This prospective
A T Fung et al.
The British journal of ophthalmology, 91(1), 62-68 (2006-09-08)
To compare the efficacy and tolerability of latanoprost versus brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. Systematic review of randomised controlled trials comparing latanoprost and brimondine, identified by searches including Medline, Embase and Cochrane Controlled
F Honrubia et al.
The British journal of ophthalmology, 93(3), 316-321 (2008-11-21)
To conduct a meta-analysis of randomised clinical trials (RCTs) in order to evaluate the development of conjunctival hyperaemia after the use of latanoprost versus travoprost and bimatoprost, in patients with ocular hypertension or glaucoma. In order to identify the potentially
Sanae Abe et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 29(1), 55-60 (2012-10-11)
To clarify the mechanism of prostaglandin (PG) analogue-dependent relaxation in ciliary arteries from wild-type (WT) and prostanoid receptor-deficient mice. The intracellular-free calcium concentration ([Ca(2+)](i)) in isolated WT mouse ciliary arteries was measured by fluorescence photometry. Reduction of [Ca(2+)](i) leading to
Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review
Russo A, et al.
Clinical Ophthalmology (Auckland, N.Z.), 2(4), 897-897 (2008)
查看所有相关文献

商品

Discover Bioactive Small Molecules for Lipid Signaling Research

Discover Bioactive Small Molecules for Lipid Signaling Research

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持